- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Marketing in the AI Age
Here in New Jersey, our home base, summer is officially upon us, and the Canadian wildfire smoke has just cleared from the air. I’m sure the bird watchers would attest to the eager chirping as both wildlife and humans greedily enjoy the beautiful weather. But even as the seasons change, so does the technology that drives innovation, as coverage in the July issue of Pharmaceutical Executive® attests.
Meg Rivers
Managing editor
Pharm Exec
In a special roundtable on how artificial intelligence (AI) is shaping pharma marketing, experts from EVERSANA/EVERSANA INTOUCH, The Janssen Pharmaceutical Companies of Johnson & Johnson, AbelsonTaylor, PharmaForceIQ, and Quilt.AI discuss:
- Harnessing the power of AI to bolster your own marketing technology strategies
- Intellectual property and content creation
- Legislation coming down the pipeline for AI
- Ethical concerns, privacy, and data security for AI, especially as it relates to pharma marketing
- AI and pharmacy marketing
We also hear from Doron Aspitz, CEO, Verix, on AI—specifically harnessing AI for pharma sales. According to Aspitz, “In commercialization, especially in sales and marketing activities, AI will play a transformative role in bringing the latest in pharma innovation to patients.” He also discusses where AI and predictive analytics “have already played a large role in getting drugs to market faster as well as improving the drug discovery process.”
I predict AI will be on the tips of everyone’s tongues in pharma—and outside of it—for some time yet.
In this month’s executive profile, Elaine Quilici, freelance writer and former editor-in-chief of Pharm Exec, interviews COMPASS Pathways’ CEO, Kabir Nath, who is making headway in the mental health space. While working at Otsuka, he honed in on Abilify (aripiprazole), which is approved to treat several different mental health conditions. Between this experience as well as a personal one with mental health—losing several loved ones to suicide—Nath continued to pursue the betterment of mental health, which (of course) led him to his role at COMPASS Pathways.
In yet another important discussion, Mike Hollan, editor, speaks with Celeste Warren, vice president for Merck and lead of the company’s Global Diversity & Inclusion Center of Excellence, in an article about diversity, equity, and inclusion (DE&I). At this point in time, while many efforts are being made, some believe the industry is still working to better understand the importance of DE&I. To date, much emphasis and responsibility have been placed on company leaders, but Warren describes in the article how there are many opportunities for employees to take positive action as well.
As ever, a huge thank you to all of the writers and experts who contributed to this issue and shared their advice and expertise. And thank you, dear reader, for tuning into another issue of Pharm Exec. There are loads of great content that you won’t want to miss.
To Tackle the Plastic Waste Crisis in Pharma, Here’s Where to Start
October 30th 2024By demonstrating big advancements in recycling, pharma companies will be much more likely to attract shareholders and other investors, giving themselves a leg up in the competition to lead the biopharmaceutical industry well into the future.
Solving One of the Hardest Questions in Cancer: How Do We Ensure Patient Access to Medicines?
October 16th 2024Pharmaceutical companies are facing new guidelines, laws, and regulations requiring a reconsideration of how to prioritize, develop, commercialize, and ultimately, secure access to medicines.
